Pennington Biomedical Research Presented at the 84th Annual American Diabetes Association Scientific Sessions

June 21, 2024 · Baton Rouge, LA

The 84th annual American Diabetes Association Scientific Sessions are taking place June 21-24 in Orlando, Fla., and several research findings from the Pennington Biomedical Research Center will be presented during the conference.

“The ADA Scientific Sessions make up the largest diabetes conference in the country, and Pennington Biomedical researchers are sought out to present our research in front of attendees from across the globe who are working to prevent and treat diabetes,” said Dr. John Kirwan, Pennington Biomedical Executive Director. “Diabetes affects more than 37 million children and adults in the United States and 537 million around the world, and the work we are doing at Pennington Biomedical is vital to our understanding of the disease and to find better methods of treatment for those living with diabetes and other chronic diseases.”

Leading physicians, scientists, and health care professionals from around the world participate in the ADA Scientific Sessions, where cutting-edge research, treatment recommendations, and advances toward a cure for diabetes will be discussed. This year’s sessions are expected to bring together more than 11,000 attendees for more than 130 speaker sessions and close to 1,500 poster presentations.

During the four-day event, the following projects from Pennington Biomedical will presented:

  • “Effects of Tirzepatide on Central Reward and Appetite Circuits in the Brain” by Dr. Owen Carmichael, Director of Biomedical Imaging
  • “SELECT – An Overview of the Study and the Weight Outcomes” by Dr. Donna Ryan, Professor Emeritus
  • “Effectiveness of Continuous Glucose Monitoring on Short-Term In-Hospital Mortality among Frail Critically Ill Patients with COVID-19 – An Exploratory, Prospective, Randomized, Open-Label, Parallel, Single-Center, Randomized Clinical Trial” by Dr. Yun Shen, Assistant Professor in the Chronic Disease Epidemiology Laboratory

During poster sessions, the following will be presented by researchers from Pennington Biomedical:

  • “Impact of Maternal Hyperglycemic and Hypertensive Disorders on Adverse Pregnancy Outcomes across the COVID-19 Pandemic – A Comprehensive Analysis in an Underserved Population” by Dr. Yun Shen, Assistant Professor in the Chronic Disease Epidemiology Laboratory
  • “Exercise Training Reverses Skeletal Muscle DRP1 Hyperactivation and Improves Respiratory Capacity in Patients with Type 2 Diabetes” by Elizabeth Heintz, Postdoc in the Integrated Physiology and Molecular Medicine Laboratory
  • “Skeletal Muscle Ubiquitin Protease Function Governs Mitochondrial Quality Control and Insulin Sensitivity in Type 2 Diabetes” by Christopher Axelrod, Director of the Integrated Physiology and Molecular Medicine Laboratory

In addition, sub-studies of the national Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes, or ARMMS-T2D,  clinical trial, of which Dr. Kirwan serves as principal investigator, will be presented at the Scientific Sessions:

  • “Quality of Life and Health Utility 12 Years after Randomization to Bariatric Surgery vs. Medical Therapy in Patients with Type 2 Diabetes and Obesity-The ARMMS-T2D Study,” presented by Dr. Donald Simonson of Brigham and Women's Hospital
  • “Association of Social Determinants of Health with Efficacy of Metabolic Bariatric Surgery (MBS) vs. Medical Therapy (MT) for Type 2 Diabetes,” presented by Dr. Mary-Elizabeth Patti of Joslin Diabetes Center

For more information contact:

Joe Coussan, Media Relations Manager,, 225-763-3049 or Ernie Ballard, Senior Director of Communications & Marketing,, 225-263-2677.

About the Pennington Biomedical Research Center

The Pennington Biomedical Research Center is at the forefront of medical discovery as it relates to understanding the triggers of obesity, diabetes, cardiovascular disease, cancer and dementia. The Center conducts basic, clinical, and population research, and is a campus of the LSU System. The research enterprise at Pennington Biomedical includes over 530 employees within a network of 44 clinics and research laboratories, and 13 highly specialized core service facilities. Its scientists and physician/scientists are supported by research trainees, lab technicians, nurses, dietitians, and other support personnel. Pennington Biomedical is a state-of-the-art research facility on a 222-acre campus in Baton Rouge. For more information, see

Pennington Biomedical Research Center
6400 Perkins Road
Baton Rouge, LA 70808